13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001224962
Total reported value
$6.7B
$6.7B
116 檔
23.8%
The Q4 2025 SEC filing reveals that Perceptive Advisors LLC held a total portfolio value of $6.7B, covering 116 public equity positions.
In Q4 2025, Perceptive Advisors LLC displayed an active expansion posture, initiating 39 new positions and adding to 32 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | Stock-Other | 10.49% | -2.59% | +27.58% | |
| 2 | CELC | Celcuity Inc | Stock-Other | 5.62% | -1.95% | +6.90% | |
| 3 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 4.86% | +0.28% | -99.39% | |
| 4 | ASND | Ascendis Pharma A/S | Stock-Other | 4.11% | -6.84% | EXIT | |
| 5 | APGE | Apogee Therapeutics Inc | Stock-Other | 3.14% | +0.08% | +72.39% | |
| 6 | ROIV | Roivant Sciences Ltd. | Stock-Healthcare | 3.09% | -0.18% | +8.37% | |
| 7 | NUVL | Nuvalent Inc-a | Stock-Other | 2.99% | -0.23% | +6.58% | |
| 8 | TVTX | Travere Therapeutics Inc | Stock-Other | 2.91% | +0.80% | +12.74% | |
| 9 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 2.39% | +0.71% | NEW | |
| 10 | EXK | Exact Sciences CORP | Stock-Materials | 2.17% | — | +157.90% | |
| 11 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 2.10% | -0.73% | +31.09% | |
| 12 | INBX | Inhibrx Biosciences Inc | Stock-Other | 2.05% | -0.05% | +9.41% | |
| 13 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 1.97% | -0.05% | +17.44% | |
| 14 | ✓ | Immatics NV | Stock-Other | 1.94% | -0.42% | +10.66% | |
| 15 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.79% | +2.03% | +149.64% | |
| 16 | AMLX | Amylyx Pharmaceuticals Inc | Stock-Other | 1.78% | — | -7.46% | |
| 17 | ACLXGBX | Arcellx Inc | Stock-Other | 1.70% | — | -40.61% | |
| 18 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.69% | -0.29% | +108.06% | |
| 19 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.66% | +0.16% | NEW | |
| 20 | AM6 | Amicus Therapeutics Inc | Stock-Other | 1.62% | — | — | |
| 21 | ZYME | Zymeworks Inc | Stock-Other | 1.53% | -0.08% | +56.02% | |
| 22 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.51% | — | — | |
| 23 | MGTX | MeiraGTx Holdings plc | Stock-Other | 1.46% | +0.44% | -18.22% | |
| 24 | AORT | Artivion Inc | Stock-Other | 1.40% | -0.58% | -14.74% | |
| 25 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 1.30% | -4.08% | EXIT | |
| 26 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.21% | -0.75% | +543.72% | |
| 27 | NRIX | Nurix Therapeutics Inc | Stock-Other | 1.20% | +0.45% | +151.09% | |
| 28 | SLDB | Solid Biosciences Inc | Stock-Other | 1.19% | +0.11% | — | |
| 29 | BLTE | Belite Bio Inc - Adr | Stock-Other | 1.18% | -0.47% | EXIT | |
| 30 | ABVX | Abivax Sa-adr | Stock-Other | 1.10% | -0.57% | +17.94% | |
| 31 | IVVD | Invivyd Inc | Stock-Other | 0.96% | -0.29% | — | |
| 32 | ✓ | Engene Holdings Inc | Stock-Other | 0.94% | -0.78% | EXIT | |
| 33 | RGEN | Repligen CORP | Stock-Healthcare | 0.92% | -0.14% | +16.68% | |
| 34 | IMVT | Immunovant Inc | Stock-Other | 0.90% | +0.01% | +25.63% | |
| 35 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 0.89% | -0.46% | +68.69% | |
| 36 | SION | Sionna Therapeutics Inc | Stock-Other | 0.86% | +0.08% | — | |
| 37 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.84% | -0.17% | EXIT | |
| 38 | DHR | Danaher CORP | Stock-Healthcare | 0.82% | +0.37% | NEW | |
| 39 | ORKA | Oruka Therapeutics Inc | Stock-Other | 0.80% | +0.58% | +16.44% | |
| 40 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.74% | -0.34% | — | |
| 41 | OMDA | Omada Health Inc | Stock-Other | 0.67% | +0.07% | — | |
| 42 | CDTX | Cidara Therapeutics Inc | Stock-Other | 0.65% | — | — | |
| 43 | IRON | Disc Medicine Inc | Stock-Other | 0.64% | — | — | |
| 44 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 0.62% | -0.54% | EXIT | |
| 45 | PEN | Penumbra Inc | Stock-Healthcare | 0.61% | — | -49.88% | |
| 46 | ANRO | Alto Neuroscience Inc | Stock-Other | 0.57% | -0.24% | +1048.51% | |
| 47 | CAI | Caris Life Sciences Inc | Stock-Other | 0.55% | — | +3.46% | |
| 48 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 0.52% | -0.02% | — | |
| 49 | PALI | Palisade Bio Inc | Stock-Other | 0.50% | -0.05% | — | |
| 50 | RAPT | Rapt Therapeutics Inc | Stock-Other | 0.50% | — | +349.12% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | PRAX | Praxis Precision Medicines I | +8.1% | +27.58% | Add |
| 2 | APGE | Apogee Therapeutics Inc | +1.6% | +72.39% | Add |
| 3 | EXK | Exact Sciences CORP | +1.4% | +157.90% | Add |
| 4 | CELC | Celcuity Inc | +1.4% | +6.90% | Add |
| 5 | SYRE | Spyre Therapeutics Inc | +1.2% | +149.64% | Add |
| 6 | BLTE | Belite Bio Inc - Adr | +1.1% | +732.01% | Add |
| 7 | DYN | Dyne Therapeutics Inc | +1% | +543.72% | Add |
| 8 | NRIX | Nurix Therapeutics Inc | +0.8% | +151.09% | Add |
| 9 | BSX | Boston Scientific CORP | +0.8% | +215.81% | Add |
| 10 | VRDN | Viridian Therapeutics Inc | +0.8% | +108.06% | Add |
| 11 | INBX | Inhibrx Biosciences Inc | +0.8% | +9.41% | Add |
| 12 | ANRO | Alto Neuroscience Inc | +0.6% | +1048.51% | Add |
| 13 | ✓ | Engene Holdings Inc | +0.5% | +179.85% | Add |
| 14 | ZYME | Zymeworks Inc | +0.5% | +56.02% | Add |
| 15 | RAPT | Rapt Therapeutics Inc | +0.4% | +349.12% | Add |
| 16 | TVTX | Travere Therapeutics Inc | +0.3% | +12.74% | Add |
| 17 | ISRG | Intuitive Surgical Inc | +0.2% | +68.69% | Add |
| 18 | EWTX | Edgewise Therapeutics Inc | +0.2% | +17.44% | Add |
| 19 | LONA | Leonabio Inc | +0.2% | +244.13% | Add |
| 20 | AM6 | Amicus Therapeutics Inc | +0.2% | — | Unchanged |
| 21 | BBNX | Beta Bionics Inc | +0.2% | +116.93% | Add |
| 22 | IMVT | Immunovant Inc | +0.2% | +25.63% | Add |
| 23 | CATBUSD | Astria Therapeutics Inc | +0.2% | — | Unchanged |
| 24 | ABVX | Abivax Sa-adr | +0.2% | +17.94% | Add |
| 25 | NAUT | Nautilus Biotechnology Inc | +0.1% | — | Unchanged |
| 26 | PTGX | Protagonist Therapeutics Inc | +0.1% | +31.09% | Add |
| 27 | KOD | Kodiak Sciences Inc | +0.1% | +33.77% | Add |
| 28 | ORKA | Oruka Therapeutics Inc | +0.1% | +16.44% | Add |
| 29 | CTNM | Contineum Therapeutics Inc-a | +0.1% | +104.95% | Add |
| 30 | RAPP | Rapport Therapeutics Inc | 0% | +66.84% | Add |
| 31 | OBIO | Orchestra Biomed Holdings In | — | -3.12% | Trim |
| 32 | CELC 2.75 08-01-31Bond | Celcuity Inc | — | — | Unchanged |
| 33 | AVTX | Avalo Therapeutics Inc | — | — | Unchanged |
| 34 | RVMDW | Revolution Medicines Inc-28 | — | — | Unchanged |
| 35 | SRZNW | Surrozen Inc-cw25 | — | — | Unchanged |
| 36 | PEPG | Pepgen Inc | 0% | — | Unchanged |
| 37 | LXEO | Lexeo Therapeutics Inc | 0% | — | Unchanged |
| 38 | ENSC | Ensysce Biosciences Inc | 0% | — | Unchanged |
| 39 | BDSX | Biodesix Inc | 0% | — | Unchanged |
| 40 | AXSM | Axsome Therapeutics Inc | 0% | — | Unchanged |
| 41 | ✓ | Envveno Medical CORP | 0% | — | Unchanged |
| 42 | IKT | Inhibikase Therapeutics Inc | -0.1% | — | Unchanged |
| 43 | IRD | Opus Genetics Inc | -0.1% | — | Unchanged |
| 44 | ✓ | Crescent Biopharma Inc. | -0.1% | — | Unchanged |
| 45 | SEPN | Septerna Inc | -0.1% | -20.00% | Trim |
| 46 | XENE | Xenon Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 47 | AVR | Anteris Technologies Global | -0.1% | -1.74% | Trim |
| 48 | KRYS | Krystal Biotech Inc | -0.1% | -50.00% | Trim |
| 49 | RGEN | Repligen CORP | -0.1% | +16.68% | Add |
| 50 | GOSS | Gossamer Bio Inc | -0.1% | -17.65% | Trim |
According to official SEC Form 13F filings, Perceptive Advisors LLC reported a total U.S. public equity portfolio value of $6.7B across 116 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including PRAX, CELC, RYTM) accounted for 23.8% of total reported equity market value during Q4 2025.
Top New Position Initiated
XBI
市值: $134.1M
Top Position Liquidated / Trimmed
MERUS N V
前期市值: $127.4M
During Q4 2025, Perceptive Advisors LLC's top holdings by market value included PRAX (10.5%)、CELC (5.6%)、RYTM (4.9%). The largest single position, PRAX, represented 10.5% of total portfolio value.
In Q4 2025, Perceptive Advisors LLC made 107 total portfolio adjustments, initiating 39 new buys, adding to 32 positions, trimming 21 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.